As anticipated, the quarter was lower than Q1 due to the expected decline in COVID testing. Non-Covid testing continues to be rolled out to improve revenue by the end of 2022.
The Company continues to deliver PCR testing and lateral flow tests based on travel requirements. Alternative testing is a lifestyle choice which is growing but will obviously lag regulated testing.
As at today, we have 235 clinics, with over 70% offering blood and other diagnostic testing services. The Company continues to roll out its strategy of becoming the leading aggregator of innovative technology and innovative tests, including blood and genome, while identifying additional products to enable consumers to take more control of their health and wellbeing.
H1 2022 Highlights compared to H1 2021:
H1 Revenue 52% higher than 2021.
Gross profit 38% higher than 2021.
Net comprehensive loss.
Move up to OTCQB. Commencement of trading on the OTCQB Venture Market in
Novel Food acceptance. Goodbody CBD products were listed by the FSA on the novel food list.
Phytovista Laboratories Granted Home Office License, the
MOT test. Launch of a Health diagnostic test.
CQC Registration. Confirmation of receiving
Genetic Risk Tests. Launch of the Genetic risk tests for cancer and heart disease.
Highlights Subsequent to end Q2 2022:
AGSM including Redomicile. Announcement of Annual General and Special meeting held on the 9th August to include a resolution for the redomicile of the company from
Contact:
Chief Executive Officer
T: +44 (0) 20 7971 1255
E: enquiries@goodbodyhealth.com
WEB: www.goodbodyhealth.com
(C) 2022 Electronic News Publishing, source